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Abstract We have expressed the cloned rat I¢-opioid receptor 
in human embryonic kidney 293 cells and studied the ability of 
K-selective ligands to inhibit adenylyl cyclase. In transfected 293 
cells, activation of the ic-opioid receptor by U50,488 and the 
dynorphins resulted in the inhibition of cAMP accumulation. The 
inhibitory response was sensitive to pertussis toxin and highly 
selective for ic-agonists; neither /x- nor 6-opioids were able to 
activate the K-opioid receptor. Upon co-transfection with the 
subunit of Gz, inhibition of cAMP accumulation by •-agonist 
became refractory to pertussis toxin, indicating that the K-opioid 
receptor can couple to both G~ and Gz proteins. 
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ribosylations. This concept is especially attractive since G i pro- 
teins have been shown to inhibit adenylyl cyclase and stimulate 
potassium channels [14]. However, an increasing number of 
Gi-coupled receptors appeared to have the capacity to interact 
with PTX-insensitive G proteins. For example, the dopamine- 
D 2 and adenosine A1 receptors can interact with Gz [15] while 
the C5a receptor can stimulate phospholipase C via Gl6 [16]. 
Thus far, there is no indication of the possible coupling of 
PTX-insensitive G proteins to x-opioid receptors. In this study, 
we report hat the rat ICl-opioid receptor is capapble of inhibit- 
ing adenylyl cyclase via the pertussis toxin-insenitive G protein, 
G z . 
2. Materials and methods 
1. Introduction 
The opioid peptides are known to regulate diverse physiolog- 
ical functions ranging from analgesia to the regulation of gas- 
trointestinal motility. The actions of opioid peptides are mani- 
fested through a number of specific opioid receptors. Amongst 
the different classes of opioid receptors (/.t, ~, and x), the x- 
opioid receptors are activated by dynorphin-related peptides. 
Based on pharmacological prolfiles, the x-opioid receptors can 
be further classified into x~ and x2 subtypes [1]. 
Intense cloning efforts have resulted in the isolation of 
cDNAs encoding the mouse [2], rat [3,4], and guinea pig [5] 
tq-opioid receptors. Like the cloned/1- [6] and ~-opioid [7] 
receptors, these xl-receptors belong to the superfamily of G 
protein-coupled serpentine r ceptors. Indeed, x-opioid recep- 
tors are known to regulate voltage dependent calcium [8,9] and 
potassium [10] channels via G proteins. The evidence for the 
inhibition of adenylyl cyclase by x-opioids is somewhat more 
controversial. Several recent reports uggest that x-opioids can 
inhibit adenylyl cyclase [11,12] whereas others failed to demon- 
strate similar esponses [13]. However, expression of the cloned 
x-opioid receptors in COS cells has revealed that this receptor 
can in fact inhibit adenylyl cyclase [2,4,5]. 
The specificity of interactions between the x-opioid receptor 
and G proteins are poorly defined. It is generally believed that 
the x-opioid receptors are coupled to Gi-like proteins which 
serve as substrates for pertussis toxin (PTX) catalyzed ADP- 
2.1. Materials 
The x~-opioid receptor (in the pcDNA3 vector) was isolated from a 
rat cDNA library [3]. The cDNAs Of~z in pcDNAI and the rat luteiniz- 
ing hormone receptor (LHR) were constructed orobtained as previ- 
ously described [15]. PTX was purchased from List Biological Labora- 
tories (Campbell, CA). Human choriogonadotropin (hCG) was a 
generous gift from the National Pituitary Agency (Bethesda, MD). 293 
cells were obtained from the American Type Culture Collection (ATCC 
CRL-1573). [2-3H]Adenine was purchased from Amersham Corp. Plas- 
mid purification columns were obtained from Qiagen Inc. Cell culture 
reagents were obtained from Gibco and all other chemicals were pur- 
chased from Sigma. 
2.2. Transient transfection of 293 cells 
Human embryonic kidney 293 cells were maintained at 5% CO2, 
37°C in Earle's minimum essential medium (MEM) supplemented with 
10% fetal calf serum, 50 units/ml penicillin and 50/.tg/ml streptomycin. 
Cells were seeded in 12-well plates at 2 x 105 cells per well the day before 
transfection. The various cDNAs were purified via Qiagen columns and 
transfected using the DEAE-dextran method as previously described 
[17]. 
2.3. cAMP accumulation 
Cells were labelled 16-20 h post-transfection with 1 /.tCi/ml of 
[2-3H]adenine with or wthout 100 ng/ml of PTX. 16-24 hours later they 
were washed once with HEPES buffered MEM (pH 7.4) and incubated 
for 30 min at 37°C in the presence of 1 mM 1-methyl-3-isobutylxan- 
thine, with or without 5 ng/ml hCG and opioid ligands as specified. The 
reaction was stopped by adding 5% TCA containing 1mM ATP. The 
[3H]eAMP fraction was isolated via the Dowex columns as described 
in [17]. Absolute values for cAMP accumulation varied between exper- 
iments, but variability within a given experiment was less than 10% in 
general. 
3. Results and discussion 
*Corresponding author. Fax: (852) 358 1559. 
Abbreviations: DPDPE, [D-Pen2,D-PenS]enkephalin; DADLE, [D-AIa2, - 
D-LeuS]enkephalin; DAMGO, [D-Ala2,N-Me-Phe4,GlyS-ol]enkephalin; 
G protein, guanine nucleotide-binding re ulatory protein; ~z, ~ subunit 
of the G protein Gz; PTX, pertussis toxin; hCG, human choriogona- 
dotropin; LHR, luteinizing hormone receptor. 
We have previously established that the cloned rat tc~-opioid 
receptor can activate Ca2+-dependent C1- channels when ex- 
pressed in Xenopus oocytes [3]. In this report we used a mam- 
malian expression system to study the receptor's ability to in- 
hibit adenylyl cyclase through different G proteins. The human 
embryonic kidney 293 cells were co-transfected with cDNAs 
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Fig. 1. U50,488-mediated inhibition of cAMP accumulation i trans- 
fected 293 cells. 293 Cells were transiently transfected, labelled with 
[2-3H]adenine and then assayed for cAMP accumulation as described 
in section 2. (A) Cells were transfected with cDNAs encoding the LHR 
(0.15 ~tg/ml) with or without x~-opioid receptor (0.25 ~tg/ml). Trans- 
fected cells were assayed for responses to hCG (5 ng/ml) with or without 
U50,488 (100 nM). *U50,488 significantly reduced the hCG-stimulated 
activity; paired t-test, P < 0.05. (B) Cells were transfected with cDNAs 
encoding the LHR (0.15 /lg/ml) and varying concentrations of the 
x~-opioid receptor (up to 3 pg/ml). Results are expressed as% inhibition 
of the hCG-stimulated activity as compared with that measured in the 
absence of the x-agonist. U50,488 (100 nM) significantly inhibited the 
hCG-stimulated activity at all cDNA concentrations tested; paired 
t-test, P < 0.05. Data shown represent the mean _+ S.D. of triplicate 
determinations in a single experiment; wo additional experiments 
yielded similar results. 
encoding the rat luteinizing hormone receptor (LHR in the 
pCIS vector) and the rat Xl-opioid receptor. Co-expression of 
LHR allows us to selectively study the sub-population of cells 
that have taken up the cDNAs, and activation of LHR by 
human chorionic gonadotropin (hCG) is used to raise the intra- 
cellular cAMP levels. As indicated in Fig. 1A, addition ofhCG 
to 293 cells transiently transfected with LHR-pCIS boosted 
intracellular cAMP levels by 19-fold above basal. In the pres- 
ence of 100 nM of U50,488, a x-selective ligand, the hCG- 
stimulated cAMP accumulation was reduced by 60-70%. Inhi- 
bition of cAMP accumulation by U50,488 was dependent on 
the amount of Xl-opioid receptor cDNA used in the transfec- 
tions (Fig. 1B) and was not seen in cells transfected with LHR- 
pCIS alone (Fig. 1A). 
We then verified the pharmacological profile of the x~-opioid 
receptors that were expressed in 293 cells by examining the 
ability of different opioid ligands to activate 1q-receptors. In 
293 cells co-transfected with cDNAs encoding LHR (0.15/~g/ 
ml) and xl-receptors (0.25 pg/ml), U50,488 dose-dependently 
inhibited the hCG response (Fig. 2) with an ECs0 of 1.4 + 0.4 
nM (mean + S.E.M.; n = 3). Dyn 1 8, a non specific opioid 
agonist also inhibited the hCG response in a dose dependent 
manner, yielding an ECs0 of 0.32 + 0.2 nM (n = 3) but with a 
slightly lower average maximal inhibition of 55% (Fig. 2). 
DAMGO and DPDPE (/1- and ~-selective agonists, respec- 
tively) had little or no effect on the hCG response. Their ECs0 
values were greater than 1 pM (data not shown). At a single 
saturating dose of 100 nM, other p- and/or ~-selective ligands 
were also unable to elicit x-opioid receptor mediated inhibition 
of the hCG response. For example, the hCG responses in the 
presence of morphiceptin or DADLE were 107 + 16% and 
107 -+ 7%, respectively, of those determined in the absence of 
opioid ligands. Nor-binaltorphimine, a specific ~¢ antagonist, 
significantly (P < 0.05) abolished the ability of U50,488 to in- 
hibit cAMP accumulation (Fig. 2). These results are consistent 
with the known pharmacological profile of the cloned Xl-opioid 
receptor [18]. 
Both p- and ~-opioid receptors are coupled to the PTX- 
sensitive G~/Go proteins [19], and Gi-like proteins have also 
been implicated in the coupling of x-opioid receptors to their 
effectors [20]. We therefore xamined the possible involvement 
of Gi proteins in xl-opioid receptor mediated inhibition of 
cAMP accumulation. In 293 cells co-expressing the LHR and 
x~-receptor, activation of the latter by 100 nM of U50,488 
significantly inhibited the hCG response (Figs. 2 and 3) and this 
effect was PTX-sensitive (Fig. 3), indicating the involvement of 
Gi proteins. For many Gi-coupled receptors, the PTX-insensi- 
tive Gz protein [21] can functionally replace Gi in the negative 
regulation of adenylyl cyclase [15]. Indeed, we have recently 
demonstrated that the cloned ~-opioid receptor can inhibit ade- 
nylyl cyclase via Gz in co-transfected 293 cells [22]. Thus we 
sought to examine if similar coupling between Gz and the 
xl- opioid receptor may exist. When the cDNA encoding the 
a subunit of Gz was included in the transfection medium, 
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Fig. 2. Dose-dependent effects of x-selective ligands. 293 cells were 
co-transfected with cDNAs encoding the LHR (0.15/.tg/ml) with or 
without xropioid receptor (0.25 ¢zg/ml), and assayed for cAMP accu- 
mulation after exposure to varying concentrations of x-selective ag- 
onists (U50,488 and dynorphin 1-8) in the absence or presence of 1 pM 
of the x-antagonist, nor-binaltorphimine (BNI). Data shown represent 
the mean + S.E.M. of triplicate determinations from three independent 
experiments. 
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Fig. 3. I¢-Opioid receptor coupling to the PTX-insensitive ~z. 293 cells 
were co-transfected with cDNAs encoding the LHR (0.15 pg/ml) and 
the x-opioid receptor (0.25 pg/ml) with or without ~z (0.125/lg/ml). 
Transfected cells were treated in the absence or presence of PTX (100 
ng/ml) and assayed for cAMP accumulation i  the presence of hCG 
(5 ng/ml) with or without 100 nM U50,488. The data represent tripli- 
cate determinations i  a single experiment; two independent experi- 
ments yielded similar esults. *U50,488 significantly reduced the hCG- 
stimulated activity; paired Bonferroni t-test, P < 0.05. 
U50,488-mediated inhibition of the hCG response became re- 
fractory to PTX treatment (Fig. 3). The retainment of the 
U50,488 response following the inactivation of endogenous G~ 
proteins by PTX indicated that the x~-opioid receptor can func- 
tionally interact with Gz. The significance of this finding is 
presently unclear. In terms of distribution, Gz is most highly 
expressed in the brain and retina with lesser concentrations in 
the adrenal gland, kidney and pancreatic islet cells [21]. It is 
noteworthy that Gz might be involved in the p/d mediated 
supraspinal antinociceptive pathways [23]. 
In this study, we report for the first time that the cloned rat 
lCl-opioid receptor can couple to a PTX-insensitive G protein, 
Gz, to inhibit adenylyl cyclase. It remains to be determined 
whether the Xl-opioid receptor can utilize additional PTX-in- 
sensitive G proteins (e.g. Gq and G12) to perform other signaling 
functions uch as inhibition of phospholipase C [24]. 
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